Biopharmaceutical Company
Appears in 1 story
Awaiting FDA decision on sparsentan for FSGS
No FDA-approved treatment for focal segmental glomerulosclerosis (FSGS) has ever existed. For the 40,000 Americans with this rare kidney disease—which drives half to kidney failure within a decade—the only options have been off-label immunosuppressants with mixed results.
Updated May 21
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
